Alnylam’s patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac – Endpoints News
FierceBiotech |
Alnylam's patisiran grabs EMA accelerated review; CRISPR Therapeutics, Casebia enter mRNA deal with CureVac
Endpoints News CRISPR Therapeutics, together with its joint venture Casebia, is teaming up with CureVac to develop improved Cas9 mRNA constructs for in vivo gene editing. CureVac will also take charge of manufacturing all mRNA needed in clinical development and … BRIEF—New mRNA collaboration for CRISPR, Casebia and CureVac |
